Your session is about to expire
← Back to Search
Non-Invasive Brain Stimulation for Lewy Body Dementia (SCAN Trial)
SCAN Trial Summary
This trial will test whether stimulating certain brain regions with a non-invasive method can help reduce fluctuations in alertness for people with Lewy body dementias, which are a major source of disability.
- Lewy Body Disease
- Lewy Body Dementia
SCAN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSCAN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SCAN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a significant amount of radiation exposure in the past.You cannot have an MRI if you have a pacemaker or feel very uncomfortable in small spaces.You have signs of a major stroke or a large abnormal growth in your brain as seen on an MRI.Criterion: You are taking certain medications that affect the nervous system.You show signs of atypical parkinsonism during a neurological exam.You have a serious mental illness like bipolar disorder.You have epilepsy, stroke, multiple sclerosis, or a moderate to severe brain injury.You have had a big problem with alcohol or drugs in the recent past.You have trouble seeing or hearing that makes it hard for you to do things.Patients diagnosed with dementia with Lewy bodies based on specific criteria.People with Lewy body dementia (DLB or PDD) who experience changes in thinking and have been taking the same dose of cholinesterase inhibitors for at least 4 weeks.You have symptoms like shaking, trouble focusing, seeing things that aren't there, acting out dreams while asleep, trouble smelling, or problems with body functions like heart rate or digestion.People with Parkinson's disease dementia who have problems with attention, thinking, memory, and also show behavioral symptoms like lack of interest, feeling sad or worried, seeing or hearing things that are not there, or having strong beliefs that are not true.
- Group 1: Experimental: HD-tDCS
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor extend to individuals who possess an age of sixty-five or above?
"To be considered for this investigation, applicants must fall within the range of 50 to 90 years old. Alternatively, there are 93 trials available for those younger than 18 and 813 studies suitable for aged individuals over 65."
Do I qualify to join this scientific experiment?
"This trial seeks 18 participants between the age of 50 and 90 diagnosed with Lewy Body Disease. Additionally, these individuals must be on a stable dosage of cholinesterase inhibitors for at least 4 weeks prior to enrollment and meet either DLB or PDD criteria as defined by Emre et al. Specifically, those seeking inclusion in this study should demonstrate cognitive deficits in two out of four domains (attention, executive functions, visuo-spatial functions, free recall memory) plus one behavioral symptom such as apathy; however lack of behavioural symptoms does not bar them from participating. Other exclusionary conditions include coexistence of any abnorm"
What is the aggregate number of individuals involved in this trial?
"Affirmative. According to clinicaltrials.gov, this research endeavor is presently recruiting participants; the trial was initially posted on May 3rd 2021 and last updated on November 7th 2022. The study requires 18 individuals at 2 distinct sites to take part in it."
Are applications being accepted at this time for participation in the trial?
"Affirmative. Data posted on clinicaltrials.gov affirms that this medical trial, initially published on May 3rd 2021, is recruiting participants at the present time. A total of 18 patients need to be recruited from two separate sites."
Share this study with friends
Copy Link
Messenger